CellMax Life
1271 Oakmead Parkway
Sunnyvale
California
94085
United States
Tel: 886-0800-555-885
Website: http://cellmaxlife.com/
About CellMax Life
CellMax Life, Inc. is a precision cancer blood-testing company providing comprehensive, personalized multi-biomarker technology platforms for genetic cancer risk assessment, early detection and personalized treatment of cancer. CellMax Life’s flagship product is CellMax CRC-Protect, a multi-biomarker blood test for early detection of colorectal cancer, which is currently marketed in Taiwan.YEAR FOUNDED:
2013
LEADERSHIP:
CEO: Atul Sharan
9 articles about CellMax Life
-
CellMax Life Earns FDA Breakthrough Device Designation for Colon Cancer & Pre-Cancerous Adenomas Screening Blood Test
8/25/2021
CellMax Life, a molecular diagnostics company, announced that its FirstSight™ pre-cancer and cancer detection blood test has received Breakthrough Device Designation from the U.S. Food and Drug Administration.
-
CellMax Life and Sebela Pharmaceuticals Enter Strategic Development and Commercialization Partnership for FirstSight™ Blood Test for Detection of Colorectal Cancer and Pre-Cancer
3/23/2021
CellMax Life, a molecular diagnostics company with proprietary technology for pre-cancer and cancer detection blood tests, and Sebela Pharmaceuticals, a market leader in gastroenterology, announce the closing of a strategic development and commercial collaboration agreement, as well as CellMax's Series C financing.
-
CellMax Life Launches Zenith, a U.S. Clinical Study for the Advancement of Blood Tests for Early Cancer Detection, With the Goal of Seeking FDA Approval
5/30/2018
Study expected to improve upon ASCO GI results that showed 84 to 88 percent accuracy at a sub-$200 price point for the test
-
CellMax Life Release: Study Presented at ASCO GU 2018 Shows Circulating Tumor Cell Blood Test May Enhance Utility of PSA Screening By Reducing Unnecessary Prostate Biopsies by Up to 90%
2/6/2018
These results illustrate the test's potential to reduce unnecessary prostate biopsies by up to 90 percent.
-
Study Presented at ASCO GI 2018 Shows Circulating Tumor Cell Blood Test Detects Early Stage Colorectal Cancer And Pre-Cancer With High Accuracy
1/17/2018
The researchers enrolled 620 people over the age of 20 who were either visiting the hospital for routine colonoscopies or had confirmed colorectal cancer.
-
CellMax Life Receives Grant From Taiwan Government For CTC Cancer Early Detection System
6/15/2017
-
CellMax Life Announces Genetic Cancer Risk Test For 98 Genes, 24 Hereditary Cancers
11/16/2016
-
CellMax Life Achieves CLIA Certification & CAP Accreditation For Precision Cancer Testing Laboratories
10/18/2016
-
Bay Area's CellMax Life Nabs $14 Million, Launches Precision Cancer Testing Company for Early Detection & Optimal Management of Cancer
7/26/2016